50
Participants
Start Date
December 31, 2007
Primary Completion Date
January 31, 2011
mifepristone
Patients take mifepristone by mouth once a day. The dose is increased during scheduled timepoints during the study or until symptoms improve or the highest dosage allowed is reached. Dose escalation will be based upon weight. During clinic visits, blood pressure, glucose tolerance and blood chemistries are measured and EKG and urinalysis will be performed.
Sinai Hospital of Baltimore, Baltimore
The Center for Diabetes and Endocrine Care, Hollywood
University of Alabama at Birmingham School of Medicine, Birmingham
University of Mississippi Medical Center, Jackson
Cleveland Clinic Foundation; Dept of Endocrinology, Diabetes & Metabolism, Cleveland
University of Michigan Medical Center, Ann Arbor
Endocrinology Center at North Hills, Froedtert and Medical College of Wisconsin, Menomonee Falls
Northwestern University Feinberg Medical; Division of Endocrinology, Metabolism & Molecular Medicine, Chicago
The University of Chicago, Chicago
Oklahoma University Health Science Center, Oklahoma City
University of Texas Southwestern Medical Center, Dallas
Diabetes and Glandular Disease Clinic, San Antonio
University of New Mexico HSC, Albuquerque
AMCR Institute Inc., Escondido
Oregon Health Sciences University, Portland
Stanford University Medical Center, Stanford
Massachusetts General Hospital, Boston
Lead Sponsor
Corcept Therapeutics
INDUSTRY